← All trials
NCT07232069
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2026
- Primary completion
- Jul 31, 2031
- Completion date
- Jul 31, 2031
- First posted
- Nov 18, 2025
- Last posted
- Nov 18, 2025
- Enrollment
- 1500
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Duke UniversityLead sponsor
- Johns Hopkins UniversityCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Harvard UniversityCollaborator
- University of North Carolina at Chapel HillCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.